Fosun Pharmaceutical announced that Fuhong Hanlin, a holding subsidiary of the company, recently received approval from the State Drug Administration to conduct phase I clinical trials with HLX37 injection and HLX43 for the treatment of advanced/metastatic solid tumors. As of the date of this announcement, no similar combination drug treatment plan has been approved for marketing worldwide. As of June 2026, the Group's cumulative R&D investment for this treatment plan was approximately RMB 8.59 million. Fu Hong Hanlin plans to carry out relevant clinical research in China when conditions are met.

Fosun Pharmaceutical announced that Fuhong Hanlin, a holding subsidiary of the company, recently received approval from the State Drug Administration to conduct phase I clinical trials with HLX37 injection and HLX43 for the treatment of advanced/metastatic solid tumors. As of the date of this announcement, no similar combination drug treatment plan has been approved for marketing worldwide. As of June 2026, the Group's cumulative R&D investment for this treatment plan was approximately RMB 8.59 million. Fu Hong Hanlin plans to carry out relevant clinical research in China when conditions are met.